113 related articles for article (PubMed ID: 19955911)
1. Pharmacogenomics of taxane/platinum therapy in ovarian cancer.
Marsh S
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S30-4. PubMed ID: 19955911
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
Marsh S; Paul J; King CR; Gifford G; McLeod HL; Brown R
J Clin Oncol; 2007 Oct; 25(29):4528-35. PubMed ID: 17925548
[TBL] [Abstract][Full Text] [Related]
3. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
4. Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer.
Seamon LG; Carlson MJ; Richardson DL; Cohn DE; Fowler JM; Copeland LJ; O'Malley DM
Int J Gynecol Cancer; 2009 Oct; 19(7):1195-8. PubMed ID: 19823054
[TBL] [Abstract][Full Text] [Related]
5. A seven-gene prognostic model for platinum-treated ovarian carcinomas.
Sabatier R; Finetti P; Bonensea J; Jacquemier J; Adelaide J; Lambaudie E; Viens P; Birnbaum D; Bertucci F
Br J Cancer; 2011 Jul; 105(2):304-11. PubMed ID: 21654678
[TBL] [Abstract][Full Text] [Related]
6. Taxanes in combination with platinum derivatives for the treatment of ovarian cancer during pregnancy: A literature review
.
Zheng X; Zhu Y; Zhao Y; Feng S; Zheng C
Int J Clin Pharmacol Ther; 2017 Sep; 55(9):753-760. PubMed ID: 28737125
[TBL] [Abstract][Full Text] [Related]
7. Current status of taxane and platinum-based chemotherapy in ovarian cancer.
McGuire WP
J Clin Oncol; 2003 May; 21(10 Suppl):133s-135s. PubMed ID: 12743128
[TBL] [Abstract][Full Text] [Related]
8. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Vasey PA; Jayson GC; Gordon A; Gabra H; Coleman R; Atkinson R; Parkin D; Paul J; Hay A; Kaye SB;
J Natl Cancer Inst; 2004 Nov; 96(22):1682-91. PubMed ID: 15547181
[TBL] [Abstract][Full Text] [Related]
9. Is ATP7B a predictive marker in patients with ovarian carcinoma treated with platinum-taxane combination chemotherapy?
Katagiri H; Nakayama K; Rahman MT; Rahman M; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama S; Otsuki Y; Miyazaki K
Int J Gynecol Cancer; 2013 Jan; 23(1):60-4. PubMed ID: 23221602
[TBL] [Abstract][Full Text] [Related]
10. ABCB1 2677G>T/A genotype and paclitaxel pharmacogenetics in ovarian cancer.
Marsh S; King CR; McLeod HL; Paul J; Gifford G; Brown R
Clin Cancer Res; 2006 Jul; 12(13):4127; author reply 4127-9. PubMed ID: 16818714
[No Abstract] [Full Text] [Related]
11. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Smith JA; Ngo H; Martin MC; Wolf JK
Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
[TBL] [Abstract][Full Text] [Related]
12. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
13. Relevance of chemotherapy dose and schedule to outcomes in ovarian cancer.
Muggia FM
Semin Oncol; 2004 Dec; 31(6 Suppl 15):19-24. PubMed ID: 15726535
[TBL] [Abstract][Full Text] [Related]
14. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma.
Lavarino C; Pilotti S; Oggionni M; Gatti L; Perego P; Bresciani G; Pierotti MA; Scambia G; Ferrandina G; Fagotti A; Mangioni C; Lucchini V; Vecchione F; Bolis G; Scarfone G; Zunino F
J Clin Oncol; 2000 Dec; 18(23):3936-45. PubMed ID: 11099323
[TBL] [Abstract][Full Text] [Related]
15. Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy.
Melichar B; Fridrichová P; Tomsová M; Malírová E
Eur J Gynaecol Oncol; 2009; 30(3):323-5. PubMed ID: 19697632
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel: an alternative taxane in ovarian cancer.
Katsumata N
Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S9-S15. PubMed ID: 14661041
[TBL] [Abstract][Full Text] [Related]
17. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer.
Vasey PA
J Clin Oncol; 2003 May; 21(10 Suppl):136s-144s. PubMed ID: 12743129
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer.
Kavanagh J; Tresukosol D; Edwards C; Freedman R; Gonzalez de Leon C; Fishman A; Mante R; Hord M; Kudelka A
J Clin Oncol; 1995 Jul; 13(7):1584-8. PubMed ID: 7602347
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas.
Matsuo K; Eno ML; Im DD; Rosenshein NB
Arch Gynecol Obstet; 2010 Feb; 281(2):325-8. PubMed ID: 19455347
[TBL] [Abstract][Full Text] [Related]
20. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience.
Leiser AL; Chi DS; Ishill NM; Tew WP
Gynecol Oncol; 2007 Jun; 105(3):657-61. PubMed ID: 17395252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]